Apixaban, an oral direct Factor Xa inhibitor: Awaiting the verdict

Expert Opinion on Investigational Drugs

Volumn 17, Issue 12, 2008, Pages 1937-1945

  Carreiro, Jennifer ^a   Ansell, Jack ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

Anticoagulation; Apixaban; Factor Xa inhibitors; Oral anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; AZD 0837; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CLOPIDOGREL; DABIGATRAN; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DU 176B; ENOXAPARIN; KETOCONAZOLE; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PLACEBO; RAZAXABAN; RIVAROXABAN; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN; YM 150; ANTITHROMBIN III; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; ISCHEMIA; LUNG EMBOLISM; METASTASIS; NONHUMAN; OPTIMAL DRUG DOSE; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PROPHYLAXIS; REVIEW; SECONDARY PREVENTION; SINGLE DRUG DOSE; STROKE; TREATMENT DURATION; TREATMENT INDICATION; UNINDEXED SEQUENCE; VENOUS THROMBOEMBOLISM; ANIMAL; CHEMISTRY; DRUG SCREENING; ORAL DRUG ADMINISTRATION; THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ANTITHROMBIN III; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; PYRAZOLES; PYRIDONES; THROMBOSIS;

EID: 58149401862     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802528625     Document Type: Review

References (28)

1. Ansell J, Bergqvist D. Current options in the prevention of thromboembolic disease. Drugs 2004 ; 64 : 1-5 (Pubitemid 39280364)
2. Leadey R. Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem 2001 ; 1 : 151-159
3. Walenga J, Jeske W, Hoppensteadt D, et al. Factor Xa inhibitors: today and beyond. Curr Opin Investig Drugs 2003 ; 4 : 272-281 (Pubitemid 36534454)
4. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007 ; 5 (Suppl 1): 60-64
5. Sinha U, Ku P, Malinowski J. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Eur J Pharmacol 2000 ; 395 : 51-59 (Pubitemid 30227342)
6. Pinto D, Orwat M, Koch S, et al. Discovery pf 1-(4-methoxyphenyl)-7-oxo- 6- (4-(2-oxyopiperidin-1-yl)phenyl)-4,5,6,7- tetrahydro1-H-pyrazaolo{3,4-c] pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, effi cacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007 ; 50 : 5339-5356
7. Schumacher W, Bostwick J, Stewart A, et al. The direct factor Xa inhibitor apixaban produces broad antithrombotic activity with limited effects on bleeding time in rats. Blood (ASH Annual Meeting Abstracts) 2007 ; 110 [Abstract 4005]
8. Wong P, Watson C, Crain E, et al. Potent antithrombotic activity of apixaban, a direct factor Xa inhibitor, with minimum bleeding time effect in rabbit models of arterial thrombosis and hemostasis [abstract PW-656]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6-12; Geneva
9. Wong P, Crain E, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008 ; 6 (5): 820-829
10. Wong P, Crain E, Pinto D, et al. Dose-dependent antithrombotic effects of apixaban, an oral direct factor Xa inhibitor, in prevention and treatment of thrombosis in rabbit models of arteriovenous-shunt and venous thrombosis at doses that preserve hemostasis. Blood (ASH Annual Meeting Abstracts) 2007 ; 110 (11) [Abstract 933]
11. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003 ; 1 (7): 1504-1514
12. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin 2006 ; 22 : 471-481
13. Luettgen J, Bozarth T, Bozarth J, et al. In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor X1 inhibitor. Blood (ASH Annual Meeting Abstracts) 2006 ; 108 (11) [Abstract 4130]
14. Bauer KA. New anticoagulants: anti IIa vs anti Xa - is one better? J Thromb Thrombolysis 2006 ; 21 (1): 67-72
15. Wong P, Crain E, Watson C, et al. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. J Thromb Thrombolysis 2007 ; 24 : 43-51 (Pubitemid 46831563)
16. Wong P, Watson C, Crain E, et al. Effects of the factor Xa inhibitor apixaban on venous thrombosis and hemostasis in rabbits. Blood 2006 ; 108 : 275a
17. He K, He B, Grace J, et al. Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts) 2006 ; 108 (11):[abstract 910]
18. Jones J. BMS-562247: oral study of embryo-fetal development in rats. Bristol-Myers Squibb document. 18 January 2005
19. Frost C, Yu Z, Moore K. Apixaban, an oral direct Factor Xa inhibitor: multiple-dose safety, pharmokinetics and pharmacodynamics in health volunteers. J Thromb Haemost 2007 ; 5 (S1):PM664
20. Frost C. Food does not affect the pharmacokinetics of apixaban, an oral factor Xa inhibitor [poster T2M061]. IXth World Conference on Clinical Pharmacology and Therapeutics; 27 July - 1 August 2008; Quebec City, Canada
21. Apixaban (BMS-562247). Bristol-Myers Squibb Investigator Brochure. 22 May 2006.
22. Frost C, Lee L, Li L, et al. Apixaban does not affect the pharmacokinetics of digoxin. J Clin Pharmacol 2007 ; 47 (9): 1196 [Abstract 60]
23. Wastall P, Nepal S, Frost C, et al. A randomized, blinded, placebo and positive-controlled, crossover study to determine the effect of repeated doses of the factor Xa inhibitor apixaban on the QTc interval [abstract PII-18]. Clin Pharmacol Ther 2008 ; 83 (Suppl 1): S48
24. Lassen M, Davidson B, Gallus A, et al. The effi cacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007 ; 5 : 2368-2375 (Pubitemid 350154345)
25. Alexander JH, Wallentin L. Safety of the factor Xa inhibitor, apixaban, in combination with antiplatelet therapy after acute coronary syndromes: results from the APPRAISE-1 dose guiding trial. Presented at the European Society of Cardiology, 30 August - 3 September, 2008
26. Savelieva I, Bajpai A, Camm A. Stroke in atrial fi brillation: update on Pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 2007 ; 39 : 371-391 (Pubitemid 47263436)
27. Savelieva I, Camm J. Update on atrial fi brillation: part I. Clin Cardiol 2008 ; 31 : 55-62
28. Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost, 2008 (Epub ahead of Print) (Pubitemid 352016310)